What’s the current market cap for LabCorp stock?

LabCorp (LH) has a market cap of $22bn as of June 17, 2026.

What is the P/E ratio for LabCorp stock?

The price to earnings (P/E) ratio for LabCorp (LH) stock is 23.46 as of June 17, 2026.

Does LabCorp stock pay dividends?

Yes, the LabCorp (LH) stock pays dividends to shareholders. As of June 17, 2026, the dividend rate is $2.88 and the yield is 1.09%. LabCorp has a payout ratio of 25.52% on a trailing twelve-month basis.

When is the next LabCorp dividend payment date?

The next LabCorp (LH) dividend payment date is unconfirmed.

What is the beta indicator for LabCorp?

LabCorp (LH) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy LabCorp stock | $LH Share Price

13:30

15:10

16:45

18:25

20:00

About LabCorp

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

Ticker

$LH

Sector

Health

Primary listing

NYSE

Employees

66,385

Headquarters

Burlington, United States

Website

www.labcorp.com

LabCorp Metrics

BasicAdvanced

$22bn

23.46

$11.29

0.88

$2.88

1.09%

What the Analysts think about LabCorp

Analyst ratings (Buy, Hold, Sell) for LabCorp stock.

Bulls say / Bears say

Diagnostic segment growth guidance of 5–6% for 2026 on robust demand for its diagnostic tests, supported by steady non-urgent surgeries among older Americans (Reuters)

Raised full-year adjusted EPS guidance to $17.70–$18.35 per share and revenue outlook to $14.65–$14.80 billion after Q1 results beat expectations (revenue $3.54 billion vs $3.51 billion estimate; adjusted EPS $4.25 vs $4.09), reflecting operating leverage and margin expansion (Reuters)

Biopharma Laboratory Services revenue jumped 8.2% to $780.6 million in Q1, driven by growth in central laboratory and contract research services (Reuters)

Softening spending by biotechnology clients in its drug-development services unit could weigh on growth in the Biopharma Laboratory Services segment (Reuters)

Adverse weather conditions in Q1 resulted in an estimated $15 million decline in testing volumes, highlighting vulnerability to external operational disruptions (Reuters)

Fourth-quarter revenue of $3.52 billion missed analysts’ estimate of $3.56 billion, indicating pressure on top-line growth despite profit beats (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 15 Jun 2026.

LabCorp Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

LabCorp Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LH

Capital at risk

Market open

Upcoming events

No upcoming events